関連する実験動画
Updated: Jun 28, 2026

19:50
Interview: Protein Folding and Studies of Neurodegenerative Diseases
Published on: July 16, 2008
リンソソームにおけるタンパク質処理:神経変性疾患における新たな治療目標
R J Mayer1, M Landon, L Laszlo
1Department of Biochemistry, University of Nottingham Medical School, Queen's Medical Centre, UK.
Lancet (London, England)
|July 18, 1992
まとめ
ニューロンは多数のリソソームを有しており,これはプリオン脳症やアルツハイマー病などの神経変性疾患に関与している可能性があります. これらのライソソームをターゲットにすることで,神経損傷の治療のための新しい治療戦略を提供することができる.
科学分野:
- 神経生物学 神経生物学とは
- 細胞生物学 細胞生物学
- 病理学 パトロジー
背景:
- ニューロンはかなりの数のリゾソームを含んでおり,これは広く認識されていない特徴です.
- リソソームは,プリオン病やアルツハイマー病を含む神経変性疾患の病原化に関与しています.
- 異常なプリオンタンパク質 (PrPSc) の蓄積とβ/A4アミロイド前駆体形成は,リソソーム関連臓器細胞で発生する.
研究 の 目的:
- 神経退行性疾患の分子病原性におけるリソソームの役割を調査する.
- 治療的アプローチとしてのリゾソーム系操作の可能性を調査する.
主な方法:
- 神経退行性疾患における細胞生物学的観察と分子遺伝学的発見のレビュー.
- リンソソーム関連臓器細胞におけるタンパク質の蓄積と形成経路の分析.
主要な成果:
- リソソーム関連の臓器細胞は,異常なプリオンタンパク質 (PrPSc) とβ/A4タンパク質の生成部位として提案されています.
- リソソームから放出される水解酵素は,一次神経損傷を引き起こす可能性があります.
結論:
- 細胞生物学的洞察は,神経変性経路を理解するために重要である.
- リソソーム系を標的とする治療戦略は,神経変性疾患の治療に考慮すべきです.
関連する概念動画
The Proteasome
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
Lysosomes
Lysosomes are membrane-enclosed spherical sacs derived from the Golgi apparatus. The most important function of the lysosome is degrading macromolecules and biological polymers that are released during membrane trafficking events such as the secretory, endocytic, autophagic, and phagocytic pathways. The degradation is carried out by several hydrolytic enzymes active in an acidic environment of the lysosomal lumen. These acid hydrolases are involved in cellular processes such as cell signaling,...
Delivery Pathways to the Lysosome
Eukaryotic cells use different mechanisms to eliminate toxic waste obsolete and worn-out substances. Lysosomes play a pivotal role in this, and hence, these substances are carried to the lysosome from other parts of the cell and extracellular space through different pathways. The most elaborately studied pathways to the lysosome are the endocytic pathways.
Endocytosis
In endocytosis, the cell membrane takes up macromolecules and particles from the surrounding medium. Clathrin-mediated...
Endocytosis
In endocytosis, the cell membrane takes up macromolecules and particles from the surrounding medium. Clathrin-mediated...
Lysosomal Hydrolases
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
The Proteasome
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

